gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AKTSHealthcarePharmaceuticals

Aktis Oncology, Inc. Common stock (AKTS)

$15.20+1.74%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$15.20▼ 32.14% in range
Jan 9, 2026Low $14.59 · High $32.23Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Aktis Oncology closed at $15.20 on Nov 4, up 1.74%, 52.8% below its highest close since Mar 13. Volume of 243.4K shares was 0.64× its 20-day average (below normal).

Split-adjusted performance: -14.9% over one month, -24.1% over six months.

In the quarter ended Jun 30, 2026, revenue was $3.38M, with a net margin of -713.5%.

Short interest was 4.3M shares at the Oct 15 settlement, down 8.5% from the prior report (18.3% of float, 11.3 days to cover).

Market cap$845.4M55.6M shares
Revenue · quarter$3.4M—
Diluted EPS$-0.44—
P/E · TTM—
Net margin-713.5%Gross 100.0%
Dividend yieldNone
Range since Mar 1314.59 – 32.23−52.8% from high
Volume243.4K0.64× 20-day avg
Volatility · 60d55.2%Annualised
Short % of float18.3%11.3 days to cover
Net cash$517.3MCash $517.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −9.6%1M −14.9%3M −35.2%6M −24.1%YTD —1Y —3Y +3066.7%5Y +110.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum52
Revenue growth—
Net margin25
Value (low P/E)—
Size68

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short4.3M−8.5% vs prior
Days to cover11.3Settled Oct 15
% of float18.3%
Short vol. 10d74.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AKTSAktis Oncology$15.20+1.74%−24.1%—−713.5%—$845.4M
CYRXCryoPort$16.70+1.52%+31.6%+7.7%−20.9%—$845.8MCompare
ALMSAlumis$6.55+0.77%−74.3%−37.7%−8557.2%—$847.8MCompare
ARDXArdelyx$3.29+8.58%−53.7%+15.7%−0.6%—$849.4MCompare
ANNXAnnexon$4.33+3.34%−24.0%———$820.9MCompare
ABUSArbutus Biopharma$4.06+4.64%−8.1%−90.6%−512.0%5.3$804.3MCompare
CRVSCorvus Pharmaceuticals$10.57+7.53%−31.6%———$889.2MCompare
ANROAlto Neuroscience$23.30+2.64%−4.9%———$914.3MCompare
COLLCollegium Pharmaceutical$23.67−0.25%−35.2%+6.3%−7.5%16.1$770.6MCompare

News about Aktis Oncology

All news →
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer CompanyThe Motley Fool · May 13, 2026▲ PositiveAktis Oncology to Present at the BofA Securities Health Care ConferenceGlobeNewswire Inc. · May 6, 2026▲ PositiveAktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire Inc. · Apr 21, 2026▲ Positive

Quick answers

What does Aktis Oncology do?
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers.
What is AKTS's market cap?
$845.42M, based on the Nov 4 close of $15.20.
Does Aktis Oncology pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AKTS is sold short?
4.3M shares, 18.3% of float, as of Oct 15, 2026.
What sector is AKTS in?
Healthcare, in the Pharmaceuticals industry.

About Aktis Oncology

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.

HQ: Boston, MA79 employeesListed Jan 9, 2026aktisoncology.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology